<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/209181-pharmaceutical-composition-for-the-treatment-of-myocardial-diseases-comprising-cilobradine by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 04:04:15 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 209181:PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MYOCARDIAL DISEASES COMPRISING CILOBRADINE</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MYOCARDIAL DISEASES COMPRISING CILOBRADINE</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>Pharmaceutical composition for the treatment of myocardial diseases accompanied by hypertrophy, comprising cilobradine and a pharmaceutical carrier or diluent, characterized in that the amount of cilobradine in the composition is between 0.2 and 8.8%.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>FORM 2<br>
THE PATENTS ACT 1970 [39 OF 1970]<br>
&amp;<br>
THE PATENTS RULES, 2003<br>
             COMPLETE SPECIFICATION<br>
[See Section 10; rule 13]<br>
"PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MYOCARDIAL DISEASES COMPRISING CILOBRADINE"<br>
BOEHRINGER INGELHEIM PHARMA GMBH &amp; CO. KG (formerly known as BOEHRINGER INGELHEIM PHARMA KG), a German company of Binger Strasse 173, D-55216 Ingelheim am Rhein, Germany,<br>
The following specification particularly describes the invention and the manner in which it is to be performed:<br><br>
The present invention relates to pharmaceutical composition for the treatment of myocardial diseases comprising cilobradine,.<br>
Elevated heart rate may be treated with'bradycardiac substances, particularly Ca++ channel blockers such as diltiazem and  verapamil or  beta-receptor blockers such as atenolol,, bisoprolol, carvedolol, metoprolol or tpropanolol and Â±f  channel blockers such as zatebradine [1- (7,8-dimethoxy-1,3 , 4, 5-tetrahydro-2H-3-benzazepin-2-on-3-yl) -3- [N--methyl-N-(2-(3,4-dimethoxy-phenyl)-ethyl)-propane] (see EP-B-0 065 229), 3-[(N-(2-(3,4-dimethoxy-phenyl)-ethyl)-piperidin-3-yl) -methyl] - (7, 8-dimethoxy-l, 3,4, 5-tetrahydro-2H-3-benzazepin-2-one (see EP-B-Q'224 794) and its enantiomers cilobradine [ (+)-3-[(N- (2-(3,4-dimethoxy-phenyl)-ethyl)-    ,   piperidin-3- (S) -yl) -methyl] - (7, 8-dimethoxy-l, 3 , 4, 5-tetrahydro-2H-3-benzazepin-2-one] or alinidine [2-(N-allyl-2,6-dichloro-anilino)-2-imidazplidine), cf. also US Patent No. 3,708,485],  while zatebradine is also known to have a favourable activity in the treatment of cardiac.insufficiency (see EP-B-0 471 388.) .<br>
Moreover it is known that bradycardiac substances, particularly the abovementioned compounds, of which the if channel blockers such as zatebradine, cilobradine or alinidine, and in particular cilobradine, are preferred,  can have a beneficial effect on the symptoms of myocardial  diseases accompanied by hypertrophy,'particularly for the treatment of idiopathic hypertrophic cardiomyopathies (HCM) such as hypertrophy of the remainder of the myocardium after myocardial infarction,  ischaemic cardiomyopathy, hypertrophy of the myocardium in valve defects and myocarditis under toxic or iatrogenic influences.<br><br>
Surprisingly it has now been found that bradycardiac substances, of which the ifchannel blockers such as zatebradine, cilobradine or alinidine, and in particular cilobradine, are preferred, not only have a favourable effect on the clinical symptoms of hypertrophic cardiomyopathy, but will even induce regression of these serious heart diseases.<br>
The present invention thus relates to the new use of bradycardiac substances, particularly the abovementioned compounds, of which the if channel blockers such as zatebradine, cilobradine or alinidine, and in particular cilobradine, are preferred, to induce the regression of myocardial diseases accompanied by hypertrophy, particularly for the treatment of idiopathic hypertrophic cardiomyopathies (HCM) in humans and domestic pets.<br>
In order to achieve the effect according to the invention it is expedient to use the dosage known from the literature for the treatment of elevated heart rate for the individual bradycardiac substances. For example the single dose<br>
for cilobradine is 0.1 to 0.5 mg/kg per os, preferably 0.2 to .0.4 mg/kg, 1 to 3 x daily,<br>
for zatebradine it is 0.2 to.1 mg/kg 2 x daily and<br>
for alinidine it is 0.5 to 5 mg/kg 2 x daily.<br>
The new use of the bradycardiac substances according to the invention was investigated with the if channel blocker -cilobradine by way of example, using the following method:<br>
A cat with severe hypertrophic cardiomyopathy (heart rate about 200 beats/minute), ECG with ST accentuations as a sign of myocardial ischaemia, increased creatinine kinase activity in the plasma and in the ultrasound image, massive compression of the ventricular wall with a reduction in the ventricular<br><br>
volume and the ejection fraction, exhibited a significant improvement in clinical symptoms after treatment with the if channel blocker cilobradine (0.3 mg/kg per os, 2 x daily) (relief from pain, normal ECG, return of normal physiological activity pattern).<br>
Follow-up investigations after one year and after about 2 years' treatment surprisingly showed a regression in myocardial hypertrophy while the improvement in symptoms was maintained.<br>
The htypertrophic cardiomyopathy in the cat serves as a model for the corresponding disease in humans (Kittleson et al., Circulation 91, 3172-3180 (1999)).<br>
 Treatment with the if channel blocker cilobradine thus leads not only to an improvement in symptoms but also to regression of the disease.<br>
The present invention also relates to drug combinations, containing at least one bradycardiac substance, particularly one of the abovementioned compounds, preferably an if channel blocker, and at least one cardioactive substance such as<br>
a cardioglycoside, e.g. methyldigoxin or digitoxin,<br>
a vasodilator, e.g. nitroglycerine,<br>
an ACE inhibitor, e.g. captopril or enalapril,<br>
an angiotensin-II antagonist, e.g. losartan or telmisartan,<br>
which are also suitable for treating myocardial diseases accompanied by hypertrophy, particularly for the treatment of idiopathic hypertrophic cardiomyopathies (HCM), if a rise in heart rate can be prevented by combining them with a bradycardiac substance.<br><br>
To achieve the effect according to the invention it is convenient to use the dosages known from the literature for-the individual bradycardiac substances for the treatment of elevated heart rate and the dosages known from the literature for the cardioactive compound used.<br>
For this purpose the bradycardiac substances, either on  their own or combined with other cardioactive compounds, are formulated with one  or more conventional inert carriers and/or diluents, e.g. with maize starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethyleneglycol, propyleneglycol, stearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof, to produce conventional Galenic preparations such as plain or coated tablets, capsules, powders, suspensions, solutions, sprays or suppositories.<br>
Thus, for example, the combination consisting of cilobradine and a cardioactive compound conveniently contains 0.1 to 0.5 mg/kg, preferably'0.2 to 0.4 mg/kg of cilobradine per os<br>
plus 0.01 to 1 mg of methyldigoxin, 1 to 2 x daily,<br>
0.01 to 1 mg of digoxin, 1 x daily,<br>
0.1 to 2 mg of nitroglycerine, 2 to 3 x daily,<br>
10 to 100 mg of captopril, 1 to 2 x daily,<br>
2 to 20 mg of enalapril, 1 x daily,<br>
10 to 200 mg of losartan, 2 x daily, or<br>
20 to 80 mg of telmisartan, 1 x daily.<br>
As the partners for the if channel blockers in the drug combination additionally act on an independent biological system and if channel blockers inhibit reflex increases in heart rate, which may occur in connection with the above combination partner, these have a synergistic activity.<br><br>
The Examples that follow are intended to illustrate the invention without restricting it:<br>
Example 1<br>
Capsules containing 1.25 mcr of cilobradine<br>
Composition:<br>
1 capsule contains:<br>
lactose monohydrate       82.75 mg<br>
maize starch	55.3 mg<br>
Method of preparation<br>
The active substance, lactose monohydrate and maize starch are mixed and packed into size 4 capsules.<br>
Example 2<br>
Capsules containing 10 mcr of cilobradine<br>
Composition:<br>
1 capsule contains:<br>
lactose monohydrate       77.6 mg<br>
maize starch	51.7 mg<br>
Method of preparation<br>
The active substance, lactose monohydrate and maize starch are mixed and packed into size 4 capsules.<br><br><br>
Example 3<br>
Tablets containing 7.5 mg of cilobradine<br>
Composition:<br>
1 tablet contains:<br>
active substance	7.5 mg<br>
maize starch	59.5 mg<br>
lactose	48.0 mg<br>
polyvinylpyrrolidone	4.0 mg<br>
magnesium stearate	1.0 mg<br>
120.0 mg<br>
Method of preparation<br>
The active substance, maize starch, lactose and polyvinylpyrrolidone are mixed and moistened with water. The moist mixture is forced through a sieve with a 1.5 mm mesh and  dried at 45Â°C. The dry granules are passed through a sieve with a 1.0 mm mesh and mixed with magnesium stearate. The finished mixture is compressed in a tablet press with punches 7 mm in diameter provided with a dividing notch, to form tablets. Weight of tablet: 120 mg<br>
Example 4<br>
Coated tablets containing 5 mg of cilobradine<br>
1 tablet core contains:<br>
active substance	5.0 mg<br>
maize starch	41.5 mg<br>
lactose     	30.0 mg<br>
polyvinylpyrrolidone	3 . 0 mg<br>
magnesium stearate	0.5 mg<br>
8 0.0 mg<br><br>
Method of preparation<br>
The active substance, maize starch, lactose and polyvinylpyrrolidone are mixed thoroughly and moistened with water. The moist mass is forced through a sieve with a 1.0 mm mesh and dried at 45Â°C, then the granules are passed through the same sieve.  After mixing with magnesium stearate, convex tablet cores with a diameter of 6 mm are compressed in a tablet-making machine. The tablet cores thus produced are  -coated in known manner with a coated consisting essentially of sugar and talc. The finished coated tablets are polished with wax. Weight of coated tablet: 130 mg<br>
Example 5<br>
Ampoules containing 5'mg.of cilobradine<br>
1 ampoule contains:<br>
active substance	5.0 mg<br>
sorbitol	-50.0 mg<br>
water for injections	ad            2.0 mg<br>
Method of preparation<br>
In a suitable mixing vessel the active substance is dissolved in water for injections and the solution is made isotonic with sorbitol.<br>
After filtration through a diaphragm filter, the solution is transferred into purified and sterilised ampoules under N2 and autoclaved for 20 minutes in a stream of water vapour.<br><br>
Example 6<br>
Suppositories containing 10 mg of cilobradine<br>
1 suppository contains:<br>
active substance	0.010 g<br>
hard fat (e.g. Witepsol H 19 and "W 45)    1.690 g<br>
1.700 g<br>
Method of preparation<br>
The hard fat is melted. At 3 8Â°C the ground active substance is homogeneously dispersed in the melt. This is cooled to 35Â°C and poured into slightly chilled suppository moulds.<br>
Example 7<br>
Drops solution containing 10 mg of cilobradine<br>
100 ml of solution contain:<br>
active substance	'          0.2  g<br>
hydroxyethylcellulose	0.15 g<br>
tartaric acid	0.1  g<br>
sorbitol solution, 70 %	dry matter  30.0  g<br>
glycerol	10.0  g<br>
benzoic acid	0.15 g<br>
dist. water	ad    100   ml<br>
Method of preparation<br>
The distilled water is heated to 70Â°C. The hydroxyethylcellulose, benzoic acid and tartaric acid are dissolved therein with stirring. The solution is cooled to ambient temperature and the glycerol and the sorbitol solution are added with stirring. At ambient temperature the active substance is added and the mixture is stirred to dissolve it completely. It is then evacuated with stirring to. eliminate air from the syrup.<br><br>
WE CLAIM:<br>
1.	Pharmaceutical composition for the treatment of myocardial diseases accompanied by hypertrophy, comprising cilobradine and a pharmaceutical carrier or diluent, characterized in that the amount of cilobradine in the composition is between 0.2 and 8.8%.<br>
2.	Pharmaceutical composition as claimed in claim 1, wherein it further contains an angiotensin-II antagonist in an amount comprised between 10 to 200 mg.<br>
3.	Pharmaceutical composition as claimed in claim 2, wherein the angiotensin-II antagonist is telmisartan and in that it is present in the composition in an amount comprised between 20 to 80 mg.<br>
Dated this 17th day of September, 2002.<br>
[DEEPAK MUNDRA]                 OF REMFRY &amp; SAGAR<br>
ATTORNEY FOR THE APPLICANTS</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDEyNzQtbXVtLWNhbmNlbGxlZCBwYWdlcygxNC0xMS0yMDA2KS5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2002-01274-mum-cancelled pages(14-11-2006).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDEyNzQtbXVtLWNsYWltcyhncmFudGVkKS0oMTQtMTEtMjAwNikuZG9j" target="_blank" style="word-wrap:break-word;">in-pct-2002-01274-mum-claims(granted)-(14-11-2006).doc</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDEyNzQtbXVtLWNsYWltcyhncmFudGVkKS0oMTQtMTEtMjAwNikucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2002-01274-mum-claims(granted)-(14-11-2006).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDEyNzQtbXVtLWNvcnJlc3BvbmRlbmNlKDA5LTA4LTIwMDcpLnBkZg==" target="_blank" style="word-wrap:break-word;">in-pct-2002-01274-mum-correspondence(09-08-2007).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDItMDEyNzQtTVVNLUNPUlJFU1BPTkRFTkNFKDI2LTMtMjAxMCkucGRm" target="_blank" style="word-wrap:break-word;">IN-PCT-2002-01274-MUM-CORRESPONDENCE(26-3-2010).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDEyNzQtbXVtLWNvcnJlc3BvbmRlbmNlKGlwbyktKDIyLTA4LTIwMDcpLnBkZg==" target="_blank" style="word-wrap:break-word;">in-pct-2002-01274-mum-correspondence(ipo)-(22-08-2007).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDEyNzQtbXVtLWVuZ2xpc2ggdHJhbnNsYXRpb24oMTctMDktMjAwMikucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2002-01274-mum-english translation(17-09-2002).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDEyNzQtbXVtLWZvcm0gMTMoMDUtMDUtMjAwMykucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2002-01274-mum-form 13(05-05-2003).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDEyNzQtbXVtLWZvcm0gMTMoMTYtMDgtMjAwNykucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2002-01274-mum-form 13(16-08-2007).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDEyNzQtbXVtLWZvcm0gMTgoMzAtMTEtMjAwNSkucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2002-01274-mum-form 18(30-11-2005).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDEyNzQtbXVtLWZvcm0gMWEoMTQtMTEtMjAwNikucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2002-01274-mum-form 1a(14-11-2006).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDEyNzQtbXVtLWZvcm0gMWEoMTYtMDgtMjAwNykucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2002-01274-mum-form 1a(16-08-2007).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDEyNzQtbXVtLWZvcm0gMihncmFudGVkKS0oMTQtMTEtMjAwNikuZG9j" target="_blank" style="word-wrap:break-word;">in-pct-2002-01274-mum-form 2(granted)-(14-11-2006).doc</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDEyNzQtbXVtLWZvcm0gMihncmFudGVkKS0oMTQtMTEtMjAwNikucGRm" target="_blank" style="word-wrap:break-word;">in-pct-2002-01274-mum-form 2(granted)-(14-11-2006).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=SU4tUENULTIwMDItMDEyNzQtTVVNLUZPUk0gMjYoMjYtMy0yMDEwKS5wZGY=" target="_blank" style="word-wrap:break-word;">IN-PCT-2002-01274-MUM-FORM 26(26-3-2010).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDEyNzQtbXVtLWZvcm0gMygxNC0xMS0yMDA2KS5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2002-01274-mum-form 3(14-11-2006).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDEyNzQtbXVtLWZvcm0gMygxNy0wOS0yMDAyKS5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2002-01274-mum-form 3(17-09-2002).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDEyNzQtbXVtLWZvcm0gNSgxNy0wOS0yMDAyKS5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2002-01274-mum-form 5(17-09-2002).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDEyNzQtbXVtLXBjdC1pcGVhLTQwOSgxNy0wOS0yMDAyKS5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2002-01274-mum-pct-ipea-409(17-09-2002).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDEyNzQtbXVtLXBldGl0aW9uIHVuZGVyIHJ1bGUgMTM3KDE0LTExLTIwMDYpLnBkZg==" target="_blank" style="word-wrap:break-word;">in-pct-2002-01274-mum-petition under rule 137(14-11-2006).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDEyNzQtbXVtLXBldGl0aW9uIHVuZGVyIHJ1bGUgMTM4KDE0LTExLTIwMDYpLnBkZg==" target="_blank" style="word-wrap:break-word;">in-pct-2002-01274-mum-petition under rule 138(14-11-2006).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDEyNzQtbXVtLXBvd2VyIG9mIGF1dGhvcml0eSgxNC0xMS0yMDA2KS5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2002-01274-mum-power of authority(14-11-2006).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=aW4tcGN0LTIwMDItMDEyNzQtbXVtLXBvd2VyIG9mIGF1dGhvcml0eSgxNy0wOS0yMDAyKS5wZGY=" target="_blank" style="word-wrap:break-word;">in-pct-2002-01274-mum-power of authority(17-09-2002).pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="209180-a-heart-actuator-device-utilized-in-heart-assist-apparatus.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="209182-laundry-treatment-granule.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>209181</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>IN/PCT/2002/01274/MUM</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>35/2007</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>31-Aug-2007</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>22-Aug-2007</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>17-Sep-2002</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>BOEHRINGER INGELHEIM PHARMA GMBH &amp; CO. KG (FORMERLY KNOWN AS BOEHRINGER INGELHEIM PHARMA KG)</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>BINGER STRASSE 173, D-55216 INGELHEIM AM RHEIN, GERMANY</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>JURGEN DAMMGEN</td>
											<td>MITTELBUCHERSTR, 1/2 88416 OCHSENHAUSEN, GERMANY</td>
										</tr>
										<tr>
											<td>2</td>
											<td>BRIAN GUTH</td>
											<td>KIRCHENSTEIGE 12, 88447 WARTHAUSEN, GERMANY</td>
										</tr>
										<tr>
											<td>3</td>
											<td>RANDOLPH SEIDLER</td>
											<td>BUCHAUR STRASSE 5/1, D-88441 MITTELBIBERACH, GERMANY</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K31/00</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/EP01/04034</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2001-04-07</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>100 18 401.4</td>
									<td>2000-04-13</td>
								    <td>Germany</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/209181-pharmaceutical-composition-for-the-treatment-of-myocardial-diseases-comprising-cilobradine by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 04:04:16 GMT -->
</html>
